Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Guanylate cyclase 1 soluble subunit beta 2 (pseudogene) (GUCY1B2)
- Target
- GUCY1B2
- Molecular classification
- Other (pseudogene)
01
Overview
Guanylate cyclase 1 soluble subunit beta 2 (GUCY1B2) is annotated as a *pseudogene* in humans and therefore does not encode a functional protein product. While predictions exist about possible guanylate cyclase activity and involvement in cGMP-mediated signaling, there is no evidence that GUCY1B2 expresses an active protein or participates in established human physiological pathways. GUCY1B2 is structurally related to the family of soluble guanylate cyclase enzymes, which are important mediators of nitric oxide signaling via cGMP production, but, unlike other functional guanylate cyclase subunits such as GUCY1B1 or GUCY1A1, GUCY1B2 lacks demonstrated enzymatic or receptor activity in humans[6][7]. Therefore, it is not considered a therapeutic target.
- Other names
- GC-SB2Guanylate cyclase 1 solube subunit beta 2 (pseudogene)Guanylate cyclase 1, soluble, beta 2 (pseudogene)Guanylate cyclase soluble subunit beta-2Guanylate cyclase 1, soluble, beta 2GCS-Beta-2EC 4.6.1.2
Beyond the preview
Go deeper on Guanylate cyclase 1 soluble subunit beta 2 (pseudogene) (GUCY1B2).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Guanylate cyclase 1 soluble subunit beta 2 (pseudogene) (GUCY1B2).